The Women's Malignancies Branch (WMB) conducts basic, translational and clinical research on the mechanisms of cancer with emphasis on those that only or primarily affect females such as breast and ovarian cancer. Research in the laboratories of the Branch covers subjects including growth factor receptor signaling, cell survival and the induction of apoptosis, metastasis, and DNA repair and cell cycle check points. The research links basic and translational experimental cancer biology and clinical investigation.
Our clinical research translates the laboratory and pre-clinical research findings into novel mechanism-based, hypothesis driven clinical trials for patients with these diseases aimed at improving outcomes for patients and informing future laboratory and clinical efforts. The WMB provides Intramural researchers collaborative opportunities to translate their findings into clinical trials. The WMB trains scientists in laboratory and translational research; and trains medical and gynecologic oncology fellows toward development of expertise supporting their subspecialty board certification.
-
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Open - RecruitingNCI Protocol ID NCI-18-C-0034Investigator Alexandra S. Zimmer, M.D. -
Phase IIB Study of Cediranib and Olaparib Combination in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Fallopian Tubal and/or Primary Peritoneal Cancer without Germline BRCA Mutation, Who Had Prior Bevacizumab (D8488C0001) #xD;
Open - RecruitingNCI Protocol ID NCI-17-C-0172Investigator Jung-Min Lee, M.D. -
Phase I/II Study of T-DM1 alone versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Open - RecruitingNCI Protocol ID NCI-17-C-0115Investigator Alexandra S. Zimmer, M.D. -
Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid Tumors
Open - RecruitingNCI Protocol ID NCI-17-C-0100Investigator Christina M. Annunziata, M.D., Ph.D. -
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Open - RecruitingNCI Protocol ID NCI-17-C-0011Investigator Christina M. Annunziata, M.D., Ph.D. -
Phase I/II Study of the Anti-programmed Death Ligand-1 Antibody MEDI4736 in Combination with Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Open - RecruitingNCI Protocol ID NCI-15-C-0145Investigator Jung-Min Lee, M.D.Share this trial: Referral ContactsContact Name Phone Number Helen Owens 301-435-5612 Irene Ekwede 301-435-4859 Linda Sciuto 301-451-9707 Melissa Walker 301-827-3456 Nicole Houston 301-443-6431 -
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer
Open - RecruitingNCI Protocol ID NCI-14-C-0156Investigator Jung-Min Lee, M.D.Share this trial: Referral ContactsContact Name Phone Number Irene Ekwede 240 760-6126 Nicole Houston 240 760-6127
| Position | Contact Name | Contact E-mail | Contact Phone | Research Area Keywords | Number of Positions |
|---|---|---|---|---|---|
| Research Nurse | Sheryl Hollarn | sheryl.hollarn@nih.gov |
Clinical nursing, data management, patient data collection |
1 | |
| Postdoctoral Fellow | Jung-Min Lee | leej6@mail.nih.gov | 301-443-7735 |
DNA repair, cell cycle pathways, BRCA mutation |
1 |
| Postdoctoral Fellow | Stan Lipkowitz | lipkowis@navmed.nci.nih.gov |
Cbl proteins, ubiquitin, receptor tyrosine kinases, signalin |
1 |
About
The Women's Malignancies Branch (WMB) conducts basic, translational and clinical research on the mechanisms of cancer with emphasis on those that only or primarily affect females such as breast and ovarian cancer. Research in the laboratories of the Branch covers subjects including growth factor receptor signaling, cell survival and the induction of apoptosis, metastasis, and DNA repair and cell cycle check points. The research links basic and translational experimental cancer biology and clinical investigation.
Our clinical research translates the laboratory and pre-clinical research findings into novel mechanism-based, hypothesis driven clinical trials for patients with these diseases aimed at improving outcomes for patients and informing future laboratory and clinical efforts. The WMB provides Intramural researchers collaborative opportunities to translate their findings into clinical trials. The WMB trains scientists in laboratory and translational research; and trains medical and gynecologic oncology fellows toward development of expertise supporting their subspecialty board certification.
Clinical Trials
-
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Open - RecruitingNCI Protocol ID NCI-18-C-0034Investigator Alexandra S. Zimmer, M.D. -
Phase IIB Study of Cediranib and Olaparib Combination in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Fallopian Tubal and/or Primary Peritoneal Cancer without Germline BRCA Mutation, Who Had Prior Bevacizumab (D8488C0001) #xD;
Open - RecruitingNCI Protocol ID NCI-17-C-0172Investigator Jung-Min Lee, M.D. -
Phase I/II Study of T-DM1 alone versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Open - RecruitingNCI Protocol ID NCI-17-C-0115Investigator Alexandra S. Zimmer, M.D. -
Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid Tumors
Open - RecruitingNCI Protocol ID NCI-17-C-0100Investigator Christina M. Annunziata, M.D., Ph.D. -
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Open - RecruitingNCI Protocol ID NCI-17-C-0011Investigator Christina M. Annunziata, M.D., Ph.D. -
Phase I/II Study of the Anti-programmed Death Ligand-1 Antibody MEDI4736 in Combination with Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Open - RecruitingNCI Protocol ID NCI-15-C-0145Investigator Jung-Min Lee, M.D.Share this trial: Referral ContactsContact Name Phone Number Helen Owens 301-435-5612 Irene Ekwede 301-435-4859 Linda Sciuto 301-451-9707 Melissa Walker 301-827-3456 Nicole Houston 301-443-6431 -
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer
Open - RecruitingNCI Protocol ID NCI-14-C-0156Investigator Jung-Min Lee, M.D.Share this trial: Referral ContactsContact Name Phone Number Irene Ekwede 240 760-6126 Nicole Houston 240 760-6127
PI & Key Staff
Positions
| Position | Contact Name | Contact E-mail | Contact Phone | Research Area Keywords | Number of Positions |
|---|---|---|---|---|---|
| Research Nurse | Sheryl Hollarn | sheryl.hollarn@nih.gov |
Clinical nursing, data management, patient data collection |
1 | |
| Postdoctoral Fellow | Jung-Min Lee | leej6@mail.nih.gov | 301-443-7735 |
DNA repair, cell cycle pathways, BRCA mutation |
1 |
| Postdoctoral Fellow | Stan Lipkowitz | lipkowis@navmed.nci.nih.gov |
Cbl proteins, ubiquitin, receptor tyrosine kinases, signalin |
1 |
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10, Room 4B54
Bethesda, MD 20892-1361
Ph: 301-435-5608
Fax: 301-451-2745